NETRIS Pharma is pleased to announce that a "trial in progress" abstract has been accepted to the ESMO congress (European Society for Medical Oncology) taking place September 16th-20th. The corresponding...
Read More
NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA® December 31, 2020 LYON, France – NETRIS Pharma, a…
NETRIS Pharma will attend the Bio Partnering @ JPM conference that will take place Virtual (Jan 11th-15th, 2021). Our team members will be pleased to meet with you and discuss…
December 23rd, 2020 – Geneva – Switzerland and Lyon – France NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m…
NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate…
NETRIS Pharma is pleased to announce the arrival of Frédéric Le Bras, MD; as the new company Chief Medical Officer. Graduated from René Descartes University in Paris, Frédéric obtained his...
Read More
NETRIS Pharma is pleased to announce that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches…
The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…